Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Soria, Jose Miguel
TRAILRUNNER-ALZ 3, NCT06653153: A Study of Remternetug (LY3372993) in Early Alzheimer's Disease	Recruiting	3	1200	Europe, Canada, Japan, US, RoW	Remternetug, LY3372993, Placebo	Eli Lilly and Company	Alzheimer's Disease	04/29	10/30
C4951003, NCT04743141: Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine	Recruiting	3	200	Europe, US	Rimegepant (PF-07899801)	Pfizer	Acute Treatment of Migraine	06/27	06/27
REMODEL-1, NCT05147220 / 2020-005899-36: Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)	Recruiting	3	800	Europe, US, RoW	Remibrutinib, LOU064, Teriflunomide	Novartis Pharmaceuticals, Novartis Pharma AG	Relapsing Multiple Sclerosis	04/26	10/30
IIBSP-SOB-2022-109, NCT06435325: Effectiveness of a Precision Diet Based on Gene Expression Versus a Personalized Mediterranean-Style Diet in Weight Loss	Recruiting	N/A	61	Europe	Precision diet, Control diet	Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau, University of Barcelona	Overweight and Obesity	06/25	06/25